Cantor Fitzgerald Estimates Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Cantor Fitzgerald lifted their FY2025 earnings estimates for Disc Medicine in a note issued to investors on Wednesday, March 5th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($4.59) for the year, up from their prior estimate of ($5.24). The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Other analysts have also recently issued reports about the company. Wedbush reaffirmed an "outperform" rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Scotiabank lifted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Stifel Nicolaus boosted their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $89.10.

Remove Ads

Disc Medicine Trading Up 1.0 %

Shares of NASDAQ IRON traded up $0.52 during midday trading on Friday, reaching $53.89. 483,491 shares of the company were exchanged, compared to its average volume of 362,290. The stock has a market cap of $1.60 billion, a P/E ratio of -13.54 and a beta of 0.73. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $68.86. The stock has a fifty day simple moving average of $57.00 and a 200 day simple moving average of $55.92.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08.

Insider Transactions at Disc Medicine

In related news, CFO Jean M. Franchi sold 3,136 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,162.88. Following the sale, the chief financial officer now owns 69,530 shares of the company's stock, valued at $3,794,947.40. This trade represents a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pamela Stephenson sold 3,137 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,217.46. Following the sale, the insider now directly owns 69,529 shares in the company, valued at $3,794,892.82. This represents a 4.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,080 shares of company stock valued at $4,523,520 in the last 90 days. 4.24% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the 4th quarter valued at $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Disc Medicine by 399.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,103 shares of the company's stock valued at $5,903,000 after purchasing an additional 74,454 shares during the period. Woodline Partners LP increased its stake in Disc Medicine by 5.2% in the fourth quarter. Woodline Partners LP now owns 396,600 shares of the company's stock valued at $25,144,000 after purchasing an additional 19,538 shares during the last quarter. ProShare Advisors LLC lifted its position in Disc Medicine by 26.5% during the fourth quarter. ProShare Advisors LLC now owns 6,966 shares of the company's stock worth $442,000 after buying an additional 1,458 shares during the period. Finally, MPM Bioimpact LLC boosted its stake in Disc Medicine by 11.1% in the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company's stock worth $21,962,000 after buying an additional 34,640 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.